Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,708 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitors IV. A series of new derivatives containing a spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one skeleton.
Nishida H, Mukaihira T, Saitoh F, Harada K, Fukui M, Matsusue T, Okamoto A, Hosaka Y, Matsumoto M, Shiromizu I, Ohnishi S, Mochizuki H. Nishida H, et al. Among authors: matsumoto m. Chem Pharm Bull (Tokyo). 2004 Apr;52(4):406-12. doi: 10.1248/cpb.52.406. Chem Pharm Bull (Tokyo). 2004. PMID: 15056953 Free article.
Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as a factor Xa inhibitor II. Substituent effect on biological activities.
Nishida H, Miyazaki Y, Mukaihira T, Saitoh F, Fukui M, Harada K, Itoh M, Muraoka A, Matsusue T, Okamoto A, Hosaka Y, Matsumoto M, Ohnishi S, Mochizuki H. Nishida H, et al. Among authors: matsumoto m. Chem Pharm Bull (Tokyo). 2002 Sep;50(9):1187-94. doi: 10.1248/cpb.50.1187. Chem Pharm Bull (Tokyo). 2002. PMID: 12237534 Free article.
Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitors III. Effect of ring opening of piperazinone moiety on inhibition.
Nishida H, Miyazaki Y, Mukaihira T, Shimada H, Suzuki K, Saitoh F, Mizuno M, Matsusue T, Okamoto A, Hosaka Y, Matsumoto M, Ohnishi S, Mochizuki H. Nishida H, et al. Among authors: matsumoto m. Chem Pharm Bull (Tokyo). 2004 Apr;52(4):459-62. doi: 10.1248/cpb.52.459. Chem Pharm Bull (Tokyo). 2004. PMID: 15056966 Free article.
Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitors V. A series of new derivatives containing a spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one scaffold.
Saitoh F, Mukaihira T, Nishida H, Satoh T, Okano A, Yumiya Y, Ohkouchi M, Johka R, Matsusue T, Shiromizu I, Hosaka Y, Matsumoto M, Ohnishi S. Saitoh F, et al. Among authors: matsumoto m. Chem Pharm Bull (Tokyo). 2006 Nov;54(11):1535-44. doi: 10.1248/cpb.54.1535. Chem Pharm Bull (Tokyo). 2006. PMID: 17077550 Free article.
Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitors(1-6) VI. A series of new derivatives containing N,S- and N,SO2-spiro acetal scaffolds.
Saitoh F, Nishida H, Mukaihira T, Kosuga N, Ohkouchi M, Matsusue T, Shiromizu I, Hosaka Y, Matsumoto M, Yamamoto I. Saitoh F, et al. Among authors: matsumoto m. Chem Pharm Bull (Tokyo). 2007 Feb;55(2):317-23. doi: 10.1248/cpb.55.317. Chem Pharm Bull (Tokyo). 2007. PMID: 17268108 Free article.
Development and Validation of Machine Learning-Based Predictive Model for Prolonged Hospital Stay after Decompression Surgery for Lumbar Spinal Canal Stenosis.
Yagi M, Yamamoto T, Iga T, Ogura Y, Suzuki S, Ozaki M, Takahashi Y, Tsuji O, Nagoshi N, Kono H, Ogawa J, Matsumoto M, Nakamura M, Watanabe K; Keio Spine Research Group. Yagi M, et al. Among authors: matsumoto m. Spine Surg Relat Res. 2024 Feb 14;8(3):315-321. doi: 10.22603/ssrr.2023-0255. eCollection 2024 May 27. Spine Surg Relat Res. 2024. PMID: 38868786 Free PMC article.
[Validity assessment of self-reported medication use in a pharmacoepidemiologic study by comparison with prescription record review].
Yajima R, Matsumoto M, Iida M, Harada S, Shibuki T, Hirata A, Kuwabara K, Miyagawa N, Nakamura T, Okamura T, Takebayashi T. Yajima R, et al. Among authors: matsumoto m. Nihon Koshu Eisei Zasshi. 2024 Jun 13. doi: 10.11236/jph.23-110. Online ahead of print. Nihon Koshu Eisei Zasshi. 2024. PMID: 38866534 Free article. Japanese.
Beyond MABEL: An Integrative Approach to First in Human Dose Selection of Immunomodulators by the Health and Environmental Sciences Institute (HESI) Immuno-Safety Technical Committee (ITC).
Matsumoto M, Polli JR, Swaminathan SK, Datta K, Kampershroer C, Fortin MC, Salian-Mehta S, Dave R, Yang Z, Arora P, Hiura M, Suzuki M, Brennan FR, Sathish J. Matsumoto M, et al. Clin Pharmacol Ther. 2024 Jun 7. doi: 10.1002/cpt.3316. Online ahead of print. Clin Pharmacol Ther. 2024. PMID: 38847597 Review.
7,708 results